### ENDURING MATERIAL LEARNER NOTIFICATION

**MED Learning Group**

**The DETECT Initiative in Early Alzheimer’s Disease: Optimizing Collaboration and Multidisciplinary Care to Facilitate Timely Diagnosis**

**April 20, 2023 – April 20, 2024**

**Online**

**Acknowledgement of Financial Commercial Support**

Eli Lilly

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Provide an accurate and timely diagnosis of AD to allow for early disease management and/or referral to specialists.
2. Select and use the best therapeutic options for patients with AD based on up-to-date clinical data on established and emerging disease modifying therapies.
3. Employ best practices for multidisciplinary care coordination, workflows, and best practices for referral of patients.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Laura | Aibara | NA |
| Daniel | DaSilva | NA |
| Brad | Dickerson | Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Takeda, Wave Life Sciences: Consultant |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Debra | Gordon | NA |
| Jessica | McMullen | NA |
| Paul | Schulz | Hoffman-Laroche, Acadia, Lilly, AbbVie, Novartis, Janssen, Passage Bio: Contracted Research; Lilly, Biogen, Acadia: Advisor; Acadia, Lilly, Biogen: Speakers Bureau; Zymo, Amprion: Other |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email Certificate@AmedcoEmail.com